Apr 16, 2020   SOURCE: PR NewsWire

Mallinckrodt to Report Earnings Results for First Quarter 2020

STAINES-UPON-THAMES, United Kingdom, April 16, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report first quarter 2020 earnings results for the period ended March 27, 2020 on Tuesday, May 5, 2020.

A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed in three ways:

    --  At the Mallinckrodt website:
        http://mallinckrodt.com/investors/events-calendar/.
    --  By telephone: For both listen-only participants and those who wish to
        take part in the question-and-answer portion of the call, the telephone
        dial-in number in the U.S. is (877) 359-9508. For participants outside
        the U.S., the dial-in number is (224) 357-2393. Callers will need to
        provide the Conference ID of 1572379.
    --  Through an audio replay: A replay of the call will be available
        beginning at 11:30 a.m. Eastern Time on Tuesday, May 5, 2020, and ending
        at 11:59 p.m. Eastern Time on Tuesday, May 19, 2020. Dial-in numbers for
        U.S.-based participants are (855) 859-2056 or (800) 585-8367.
        Participants outside the U.S. should use the replay dial-in number of
        (404) 537-3406. All callers will be required to provide the Conference
        ID of 1572379.

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO
(314) 654-3638
daniel.speciale@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. (©) 2020 Mallinckrodt. 04/2020

View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-first-quarter-2020-301041584.html

SOURCE Mallinckrodt plc